Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Earnings for Apogee Therapeutics, Inc. (APGE)
Earnings in 2023 (TTM): $-83,985,000
According to Apogee Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-83,985,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Apogee Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-83,985,000 | $-83,985,000 |
| 2022 | $-39,785,000 | $-39,785,000 |